Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study examining the impact of an innovative clinic has highlighted its significant impact, showing a dramatic increase in the number of patients able to start clozapine safely in the community.

Five members of the TUNE-UP team in an office looking to camera
The TUNE-UP team (from eft to right): Left to right: George Chapman, Valentina Mancini, Rob McCutcheon, Christos Petrisis, Ioana Varvari

Supported by the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research (OH BRC), the Treating Unmet Needs in Psychiatry TUNE-UP is run by Oxford Health NHS Foundation Trust’s (OHFT).

Clozapine remains the only evidence‑based treatment for people with treatment‑resistant schizophrenia, yet many patients face long delays in accessing it, often because initiation typically requires an inpatient stay.

For many, this represents a major barrier to effective treatment. The TUNE-UP service was established to address this challenge by providing a dedicated, community-based pathway delivered by specialist clinicians from OHFT, working in close partnership with the University of Oxford’s Department of Psychiatry. While the clinic supports a wide range of complex clinical needs in people with severe mental illness, including medication optimisation, physical health and metabolic risk, and treatment-related side-effects; improving access to clozapine has been a key early focus.

Published in BJPsych OPEN, the findings show the scale of the clinic’s impact. During the 12 months that TUNE-UP was in operation, community clozapine initiations increased more than six‑fold compared with periods when the service was not available. Patients supported by the clinic also experienced measurable improvements in their symptoms and day‑to‑day functioning.

The TUNE‑UP team provided intensive assessment, collaborative care planning and closely monitored community‑based titration allowing suitable patients to begin clozapine without the need for hospital admission. Alongside benefits for clozapine access, the service supports broader prescribing optimisation and physical health management in a population with high levels of unmet need. This approach gives patients greater choice and control over their care, reduces reliance on inpatient admission, and helps free up specialist beds.

Senior author Robert McCutcheon, Associate Professor of Psychiatry and Honorary Consultant Psychiatrist said:

This paper highlights what’s possible when academic insight and frontline clinical expertise are brought together. By developing a safe and effective community pathway for clozapine initiation — within a wider service focused on complex treatment optimisation — we’ve been able to reach patients who might otherwise face long delays or avoid treatment altogether. The results show that targeted, collaborative services can make a real difference for people living with severe mental illness, and we hope this model will inform similar approaches across the NHS.”

With clozapine still under-utilised nationally, the authors suggest that community-focused, specialist services like TUNE-UP could offer a scalable solution not only for improving access to clozapine, but also for addressing wider unmet clinical needs and improving long-term outcomes and patient experience.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

New audit system maps how mental-health risks emerge in AI chatbot conversations

Scientists have developed a framework for stress-testing how AI chatbots respond to vulnerable users, helping researchers identify weaknesses and test ways of making mental-health interactions safer.

AI could help identify patients at risk of psychosis more quickly

AI has been shown to be effective in identifying and analysing symptoms from psychiatric interviews, which could help speed up assessments and access to care for those who need it most, according to a new study.

Clinical Trial of Ketogenic Therapy for Early Psychosis funded by Baszucki Group

The University Oxford has received £1.17m of funding from Baszucki Group to assess the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P).

New psychiatry textbook by Oxford experts published

The latest edition of the Shorter Oxford Textbook of Psychiatry has just been published by Oxford University Press.

New study offers breakthrough in detecting risk for psychosis and bipolar disorders

A study published recently in The Lancet Psychiatry has unveiled a new approach to identifying individuals at risk of developing psychotic disorders or bipolar disorder.

Simple scoring system could help clinicians identify possible cases of NMDAR-antibody encephalitis

Scientists have identified a key set of symptoms and developed a scoring system to help clinicians in frontline medical and mental health services consider the possibility of a rare form of encephalitis, which can sometimes be mistaken for psychosis.